Report shows weak US oversight of drug discount program for the uninsured

7 February 2014
new-york-big

A group of Republican Senate and House lawmakers in the USA released statements in response to a report they requested of the Office of the Inspector General (IG) of the Department of Health and Human Services (HHS).

The lawmakers asked the IG to look into the Health Resources and Services Administration’s (HRSA) oversight of the 340B Drug Pricing Program, through which prescription drug manufacturers give health safety net providers access to discounted prices on outpatient drugs. The IG report indicates that the program suffers from a lack of clear guidance from HRSA, the result of which is that “some covered entities in our study do not offer the discounted 340B price to uninsured patients at their contract pharmacies.” The report also indicates that there are insufficient safeguards in place to prevent illegal or wasteful use of taxpayer funds.

On May 6, 2013, Senators Lamar Alexander (Republican, Tennessee lead Republican on the Senate health committee; Mike Enzi (Rep, Wyoming); Orrin Hatch (Rep, Utah); and Chuck Grassley (Rep, Iowa); as well as House Energy and Commerce Health Subcommittee Chairman Joe Pitts (Rep, Pennsylvania) and Representative Bill Cassidy (Rep, Louisiana) sent a letter to the HHS Inspector General requesting examination of HRSA’s oversight of contract pharmacy arrangements to ensure that these pharmacies do not violate the terms of the 340B drug discount program.

No accountability without proper oversight

Senator Enzi said: “Without proper oversight there isn’t accountability. Without accountability we’re giving a pass to a broken program that isn’t meeting its goals of helping uninsured and low-income Americans. The Administration can do better and I expect to hear their solutions for addressing the vulnerabilities identified by the Inspector General.”

Senator Alexander said: “For the sake of the low-income Americans who should be benefitting from prescription drug discounts through this program, I expect that Secretary Sebelius will take immediate action to ensure the Health Resources and Services Administration fixes the problems uncovered by the Inspector General.”

Senator Hatch said: “It’s unacceptable that inconsistent, lax oversight has allowed the 340B program to be gamed – jeopardizing its core mission of helping low-income Americans. As this report demonstrates, it’s imperative the Health Resources and Services Administration step up to the plate and perform more aggressive oversight to better guarantee assistance for those it’s meant to serve.”

Senator Grassley said: “Congress expects the discounts to go to low-income patients, but according to this report, that isn’t always happening because of the complexities that have developed around this program. Maintaining program integrity is fundamental to the work of every federal agency. In this case, HRSA needs to faithfully execute its responsibilities or account for why it can’t do so.”

Representative Pitts said: “This report from HHS’s own watchdog raises serious questions about whether the 340B program is serving its core mission to help the uninsured. This report underscores the need for strong oversight so that the program is best suited to help those most in need.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical